Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260307 · ClinicalTrials.gov registry record · NA
Improving Spatial Perception and Speech Understanding in Multitalker Mixtures
A NA study of Hearing Loss, sponsored by Boston University Charles River Campus.
- Recruiting
- Registry status
- NA
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT05260307: Recruiting NA study of Hearing Loss, sponsored by Boston University Charles River Campus.
NCT05260307 is a NA study of Hearing Loss that is actively recruiting participants, run by Boston University Charles River Campus. The registered enrollment target is 220 participants, below the 6,117-participant average among 58 other Hearing Loss trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05260307, a NA study of Hearing Loss, is actively recruiting participants, sponsored by Boston University Charles River Campus.
- RECRUITING
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate several approaches for improving spatial perception and speech intelligibility in multitalker listening situations for hearing-aid users. The hypotheses are that spatial perception and speech intelligibility will be improved by (1) increased high-frequency audibility, (2) speech envelope enhancement, and/or (3) appropriate sound image externalization.
Primary Outcome
Speech intelligibility scores will be measured in a baseline condition (e.g. unaided) and in a number of hearing-aid conditions (post-intervention). Scale is in percent correct (0-100%).
Conditions Studied
Interventions
- OTHER hearing aid condition
Study Locations (1)
Massachusetts
- Boston University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
What NCT05260307 shows while recruiting
NCT05260307 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 6,117-participant average among 58 other Hearing Loss trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Hearing Loss appearing as the primary indexed condition, and to 1 intervention - of which hearing aid condition is the first listed.
NCT05260307 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05260307 about?
NCT05260307 is a clinical study titled "Improving Spatial Perception and Speech Understanding in Multitalker Mixtures". The purpose of this study is to investigate several approaches for improving spatial perception and speech intelligibility in multitalker listening situations for hearing-aid users. The hypotheses are that spatial perception and speech intelligibility will be improved by (1) increased high-frequency...
What is the current status of trial NCT05260307?
This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2022-03-09. Estimated completion is 2026-11-30.
What conditions does trial NCT05260307 study?
This clinical trial studies the following conditions: Hearing Loss.
What interventions are being tested in trial NCT05260307?
The interventions under investigation include: hearing aid condition (OTHER).
Who is sponsoring clinical trial NCT05260307?
This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05260307 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05260307's enrollment target sits among peer trials
220 24th of 58 higher than 35 of 58 other Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Access and Affordability of Adult Hearing Healthcare
RECRUITING · NA
-
AI Noise Reduction in Phonak Hearing Aids
RECRUITING · NA
-
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
RECRUITING · NA
-
Auditory-Cognitive Training to Optimize Outcomes for Older CI Users
RECRUITING · NA
-
Innovations in Hearing Accessibility and Technology (IHAT) Study
RECRUITING · NA
-
Clinical Utility of Residual Hearing in the Cochlear Implant Ear
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI